Preclinical Evaluation of B7-H3-specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia.
Eben I LichtmanHongwei DuPeishun ShouFeifei SongKyogo SuzukiSarah AhnGuangming LiSoldano FerroneLishan SuBarbara SavoldoGianpietro DottiPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
B7-H3 is a promising target for AML-directed CAR-T therapy. B7-H3.CAR-Ts control AML and have a favorable safety profile in preclinical models.